Mar. 13 at 11:23 AM
$ATYR PRE 14A filed 3/12/2026: Board proposes doubling authorized shares from 170M to 340M at the Annual Meeting on May 11. With ~98M shares outstanding, this creates capacity - not an immediate offering. Standard biotech housekeeping ahead of potential(!!) capital needs (ATM with Jefferies is active, next Phase 3 would cost
$50-80M+).
If the FDA Type C meeting (mid-April) greenlights a focused confirmatory study, they'll need to raise capital — but that's a good problem to have, and raising at
$1.50-2+ post-positive-minutes is very different from diluting at
$0.86 today.
https://www.sec.gov/Archives/edgar/data/1339970/000133997026000012/atyr-20260312.htm
